Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 EV-to-EBIT is 5.69 as of Aug. 06, 2026, which is 11% above its 10-year median of 5.12. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.10 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 688 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 86.34% on this metric.
Consun Pharmaceutical Group (OTCPK:CPHGF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Consun Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2025 was $459.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $169.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group EV-to-EBIT Related Terms
Consun Pharmaceutical Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's EV-to-EBIT falls into.
Consun Pharmaceutical Group's current Enterprise Value is $961.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $169.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a EV-to-EBIT of 5.69 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Consun Pharmaceutical Group and its competitors. This is 11% above median its historical median of 5.12. Over the past decade, Consun Pharmaceutical Group's EV-to-EBIT has ranged from 0.67 to 19.00. According to the industry distribution chart, Consun Pharmaceutical Group ranks #94 out of 688 companies in the Drug Manufacturers industry, placing it in the top 13.7%.
Is Consun Pharmaceutical Group's EV-to-EBIT too high?
Consun Pharmaceutical Group's current EV-to-EBIT of 5.69 is 11% above median its 10-year median of 5.12. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 19.00. The Drug Manufacturers industry median EV-to-EBIT is 15.55. Consun Pharmaceutical Group's value of 5.69 is 63.4% below this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #94 out of 688 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #94 out of 688 companies for EV-to-EBIT. This places Consun Pharmaceutical Group in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.55. Consun Pharmaceutical Group's value of 5.69 is 63.4% below this benchmark. Historically, Consun Pharmaceutical Group's own EV-to-EBIT has ranged from 0.67 to 19.00 over the past decade. While the company's 10-year median is 5.12 vs. the industry median of 15.55, Consun Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.55, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current EV-to-EBIT of 5.69 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current EV-to-EBIT is 5.69, which is 11% above median its own 10-year median of 5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.10, compared to a current price of $1.80 — trading 63.6% above its estimated fair value. The current EV-to-EBIT is 5.69, which is 11% above median its 10-year median of 5.12 and 63.4% below the Drug Manufacturers industry median of 15.55. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current EV-to-EBIT is 5.69 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 63.6% above its estimated GF Value™ of $1.10.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
EV-to-EBIT: 5.69 (11% above median its 10-year median of 5.12)
GF Value™: $1.10 vs. price of $1.80 (63.6% above fair value)
Industry Position: 63.4% below the Drug Manufacturers median (#94 of 688)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
